tetano
Editor, Senior Moderator
Cell
. 2020 Aug 6;182(3):713-721.e9.
doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6.
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Hui Wang[SUP] 1 [/SUP], Yuntao Zhang[SUP] 1 [/SUP], Baoying Huang[SUP] 2 [/SUP], Wei Deng[SUP] 3 [/SUP], Yaru Quan[SUP] 4 [/SUP], Wenling Wang[SUP] 2 [/SUP], Wenbo Xu[SUP] 2 [/SUP], Yuxiu Zhao[SUP] 1 [/SUP], Na Li[SUP] 1 [/SUP], Jin Zhang[SUP] 1 [/SUP], Hongyang Liang[SUP] 1 [/SUP], Linlin Bao[SUP] 3 [/SUP], Yanfeng Xu[SUP] 3 [/SUP], Ling Ding[SUP] 1 [/SUP], Weimin Zhou[SUP] 2 [/SUP], Hong Gao[SUP] 3 [/SUP], Jiangning Liu[SUP] 3 [/SUP], Peihua Niu[SUP] 2 [/SUP], Li Zhao[SUP] 2 [/SUP], Wei Zhen[SUP] 2 [/SUP], Hui Fu[SUP] 1 [/SUP], Shouzhi Yu[SUP] 1 [/SUP], Zhengli Zhang[SUP] 1 [/SUP], Guangxue Xu[SUP] 5 [/SUP], Changgui Li[SUP] 6 [/SUP], Zhiyong Lou[SUP] 7 [/SUP], Miao Xu[SUP] 8 [/SUP], Chuan Qin[SUP] 9 [/SUP], Guizhen Wu[SUP] 10 [/SUP], George Fu Gao[SUP] 11 [/SUP], Wenjie Tan[SUP] 12 [/SUP], Xiaoming Yang[SUP] 13 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
Keywords: BBIBP-CorV; SARS-CoV-2; inactivated vaccine.
. 2020 Aug 6;182(3):713-721.e9.
doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6.
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Hui Wang[SUP] 1 [/SUP], Yuntao Zhang[SUP] 1 [/SUP], Baoying Huang[SUP] 2 [/SUP], Wei Deng[SUP] 3 [/SUP], Yaru Quan[SUP] 4 [/SUP], Wenling Wang[SUP] 2 [/SUP], Wenbo Xu[SUP] 2 [/SUP], Yuxiu Zhao[SUP] 1 [/SUP], Na Li[SUP] 1 [/SUP], Jin Zhang[SUP] 1 [/SUP], Hongyang Liang[SUP] 1 [/SUP], Linlin Bao[SUP] 3 [/SUP], Yanfeng Xu[SUP] 3 [/SUP], Ling Ding[SUP] 1 [/SUP], Weimin Zhou[SUP] 2 [/SUP], Hong Gao[SUP] 3 [/SUP], Jiangning Liu[SUP] 3 [/SUP], Peihua Niu[SUP] 2 [/SUP], Li Zhao[SUP] 2 [/SUP], Wei Zhen[SUP] 2 [/SUP], Hui Fu[SUP] 1 [/SUP], Shouzhi Yu[SUP] 1 [/SUP], Zhengli Zhang[SUP] 1 [/SUP], Guangxue Xu[SUP] 5 [/SUP], Changgui Li[SUP] 6 [/SUP], Zhiyong Lou[SUP] 7 [/SUP], Miao Xu[SUP] 8 [/SUP], Chuan Qin[SUP] 9 [/SUP], Guizhen Wu[SUP] 10 [/SUP], George Fu Gao[SUP] 11 [/SUP], Wenjie Tan[SUP] 12 [/SUP], Xiaoming Yang[SUP] 13 [/SUP]
Affiliations
- PMID: 32778225
- DOI: 10.1016/j.cell.2020.06.008
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits, and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.
Keywords: BBIBP-CorV; SARS-CoV-2; inactivated vaccine.